Hidradenitis Suppurativa and Inflammatory Bowel Disease Strongly Linked

MedicalResearch.com Interview with:

Alexander Egeberg, MD PhD National Allergy Research Centre, Departments of Dermato-Allergology and Cardiology Herlev and Gentofte University Hospital, University of Copenhagen Hellerup, Denmark

Dr. Alexander Egeberg

Alexander Egeberg, MD PhD
Gentofte Hospital
Department of Dermatology and Allergy

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Inflammatory bowel disease (IBD) has been associated with increased prevalence of HS, but data has been limited to small studies and even less is known about the concurrence and risk of new-onset IBD in patients with pre-existing HS.

In our study, we found a higher prevalence of Crohn’s disease and ulcerative colitis in patients with HS. Notably, there was a more than two-fold increased risk of new-onset Crohn’s disease and a 63% increased risk of new-onset ulcerative colitis in patients with Hidradenitis suppurativa compared with the general population.

MedicalResearch.com: What should readers take away from your report?

Response: Hidradenitis suppurativa and Inflammatory bowel disease appears to be strongly linked, and the risk of new-onset IBD may be significantly increased in HS patients. This warrants the attention of treating physicians, in particular since this may affect the choice of systemic pharmacotherapy used in these patients.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Response: As new drugs, in particular biologics, are being developed for dermatological diseases these drugs may also be tested in patients with HS. As some of these drugs have also proven efficacy in IBD, future studies may want to focus on whether treating one condition also alleviates symptoms of the other.

Disclosures: Dr. Egeberg has received research funding from Pfizer and Eli Lilly, and honoraria as consultant and/or speaker from Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. The present study was sponsored by Eli Lilly.

MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.


Prevalence and risk of inflammatory bowel disease in patients with hidradenitis suppurativa

Alexander Egeberg, Gregor B.E. Jemec, Alexa B. Kimball, Hervé Bachelez, Gunnar H. Gislason, Jacob P. Thyssen, Lotus Mallbris
Publication stage: In Press Accepted Manuscript
Journal of Investigative Dermatology
Published online: January 14, 2017

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on MedicalResearch.com

[wysija_form id=”5″]




Last Updated on January 15, 2017 by Marie Benz MD FAAD